Cefamandole Nafate Free Base

Summary

Cefamandole Nafate Free Base (CHEMBL1201218) is an approved small-molecule antibacterial agent.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 490.5 Da · C19H18N6O6S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201218
Name	Cefamandole Nafate Free Base
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5284527
ChEBI	CHEBI:53654
Molecular formula	C19H18N6O6S2
Molecular weight	490.5
InChIKey	RRJHESVQVSRQEX-SUYBPPKGSA-N

SMILES: CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)OC=O)SC2)C(=O)O

IUPAC name: (6R,7R)-7-[[(2R)-2-formyloxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A cephalosporin compound having (R)-O-formylmandelamido and N-methylthiotetrazole side groups. It is used (as the sodium salt) as a progrug for cefamandole.

Pharmacological roles (ChEBI): antibacterial agent, prodrug.

Parent form; salt/anhydrous children: CHEMBL1618

Patent coverage: 11 distinct patent families (17 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).